The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.
The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide. The collaboration has since delivered multiple milestones across the discovery phase. Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.
"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."
Sandeep Gupta, Endo Pharmaceuticals, Senior Vice President, Discovery & Early Development , said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."